Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive south african trial tests 'Treat All' strategy to stop HIV

NCT ID NCT01509508

Prevention Sponsor: ANRS, Emerging Infectious Diseases Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This large study in South Africa tested whether offering HIV treatment to everyone right after diagnosis, instead of waiting until their immune system weakened, could reduce new HIV infections across entire communities. Over 28,000 people from 22 communities took part. The idea is that treating people early lowers the amount of virus in their body, making it much less likely to pass HIV to others.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Atripla (tenofovir/emtricitabine/efavirenz)
What this could lead to
If successful, this strategy could show that immediate HIV treatment for everyone diagnosed dramatically lowers new infections in a community, pointing toward a way to control the epidemic.
What could go wrong
This is a large trial, but results depend on real-world uptake and adherence. The strategy may not work as well in other settings or populations, and side effects from lifelong medication are a concern.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

28,153 people

The number who actually took part.

Start date

Mar 2012

Finished

Jun 2016

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 16 and more * Member of a household in the designated cluster within the Hlabisa sub-district of KwaZulu Natal in South Africa * Able and willing to give written informed consent for trial participation and/or HIV counselling and testing

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV infection

Contacts and locations

Locations

  • Hlabisa Hospital

    Hlabisa, KwaZulu-Natal, 3937, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.